Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the overall response rate of single agent TRC105 and
the combination of TRC105 and bevacizumab in patients with refractory GTN (including
choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic
tumor (ETT)). Up to 30 patients will be treated.